did not affect serum CXCL10 levels, consistent with observations in our mouse model 3 ( Supplemental  Fig 2; available at http://www.jaad.org). The most common side effects of simvastatin were self-limited myalgia in 4 participants and diarrhea in 2 participants. Three participants had mild, transient transaminitis and 4 had mild creatine phosphokinase elevations, none requiring dose modifications. Only 1 withdrawal, because of vertigo, was thought to be treatment-related.
Our study does not support the use of oral simvastatin for the treatment of vitiligo. Disparate findings in this study compared with our mouse model may be a result of dosing limitations in humans because of potential toxicity, which is not a concern in mice. Our failure to show efficacy may also have been influenced by long-standing disease in our participants (responses are best in those with recent onset), small sample size, or lack of sensitive measures of treatment response. The VASI relies on an estimation of affected BSA, with limited sensitivity to change ([4.7% BSA). 5 Newer outcome measures may provide more sensitive options for monitoring responses. Simvastatin may induce myopathy at higher doses; however, topical treatment may allow the delivery of sufficiently high local concentrations without systemic toxicity and could be tested in larger studies.
Increased blood levels of NKG2D
1 CD4 2 It is well known that CD4 1 T cells highly infiltrate the tissue of the ''bee swarm'' in AA. 3 However, the functional role and expression patterns of NKG2D
1 CD4 1 T cell in AA remain largely unknown. In this study, we investigated the changes in blood levels of NKG2D 1 CD4 1 T cells in patients with AA.
Forty-three patients with AA (18 men and 25 women) and 26 healthy controls (10 men and 16 women) with no scalp lesions in their personal history or on clinical examination were enrolled. The cell surface expression of NKG2D on peripheral blood mononuclear cells was studied by flow cytometry analysis (FACS Aria; BD Biosciences, Franklin Lakes, NJ). Results in each group were expressed as a percentage of CD4
1 T cells, CD8 shows the representative results taken from the third experiment (10 healthy controls and 10 patients with AA). 
T cells, or CD56
1 NK cells expressing NKG2D. We collected blood samples 4 times, and the FACS analysis was also performed by dividing into 4 times. Therefore, final data were represented as a fold change of each cells expressing NKG2D over the healthy control (control set to 1). The patients were segregated into 2 or 3 subgroups according to AA severity, activity, type, and treatment modalities for subgroup analysis. Statistical analysis was performed using the ManneWhitney U test and KruskaleWallis analysis. Double-labeling immunofluorescence microscopy in 2 representative cases using freshly frozen specimens was also performed.
The results showed that the levels of NKG2D 1 CD8 1 T cells and NKG2D 1 CD56 1 NK cells were higher in the AA group compared with the control group (P \ .05). Interestingly, a 2.49-fold increase in the CD4 1 T cells subset expressing NKG2D was detected in the peripheral blood from patients with AA compared with healthy controls (P \ .05; Fig 1) . Although not statistically significant, the proportion of NKG2D 1 CD4 1 T cells was lower in patients who had mild severity AA and in those who received systemic immunosuppressive therapy. Double label immunofluorescence revealed NKG2D 1 cells coexpressed CD4 around the hair follicles of the AA lesion (Fig 2) .
Recently, the role of NKG2D 1 CD4 1 T cells in other chronic autoimmune diseases, such as Crohn's disease and rheumatoid arthritis, was highlighted. 4 A subset of CD4 1 T cells expressing NKG2D was higher in the lamina propria of patients with Crohn's disease. 5 These NKG2D 1 CD4 1 T cell clones were functionally active through major histocompatibility complex class I-related chain A (MICA) eNKG2D interactions, producing IFN-and killing targets expressing MICA. 5 We hypothesize that NKG2D 
